IMNM Immunome, Inc.: Forward P/S Multiple
Intellectual property protection via an antibody patent portfolio creates a significant barrier to entry for competitors. The expected P/S multiple visualizes this resilience, where 741.00 captures the magnitude of this parameter. Immunome, Inc. (IMNM) relies on the discovery of rare antibodies for targeted cancer therapy, although the company is currently deploying capital toward costly clinical trials prior to the launch of commercial sales.
Metric breakdowns and analytics for immunome.com (IMNM)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- company liabilities and liquidity data:
- business earnings and investment ratios data:
IMNM - Company Net Income|Future Profit Immunome, Inc.|IMNM - Company Value to Net Income|Forward P/E Multiple immunome.com|IMNM - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Immunome Corp|IMNM - Operating profit before amortization|Net earnings per share (EPS TTM) Immunome|IMNM - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months immunome.com|IMNM - Expected net earnings per share growth this year|Earnings growth forecast for next year Immunome, Inc.
- sales and revenue data:
Fundamental company valuation:IMNM (immunome.com)
For Immunome, Inc. (IMNM), the combination of Clay Sigall's high reputation and revenue valuation determines its investment attractiveness. The current forward P/S ratio correlates the company's market value with projected sales volume, revealing that the asset is overbought. This indicator allows for the timely detection of speculative spikes, separating them from real growth. During a period of structural management adaptation, this metric serves as a filter to verify the validity of market optimism.
Competitor analysis
Forward P/S Multiple ARGX (argenx.com)|BioNTech Group (BNTX) - Market Cap to Future Revenue Ratio|ABIVAX - Forward P/S Multiple|ADMA - Forward P/S Multiple|Protagonist (PTGX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Immunovant Inc|Price-to-Projected Revenue Ratio Kiniksa Pharmaceuticals|Grifols Group (GRFS) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Adaptive Biotechnologies Corp (ADPT)|Price-to-Projected Revenue Ratio CLDX (Celldex Therapeutics)|Price-to-Projected Revenue Ratio Aurinia Pharma AUPH|Forward Price to Sales BCRX|VERA: Forward Price-to-Revenue Multiple|Forward Price to Sales DNTH (Dianthus Therapeutics)|Pharvaris N.V. (PHVS) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio AbCellera Biologics (ABCL)|TRML (Tourmaline Bio Inc) - Forward P/S Multiple|Market Cap to Projected Revenue PGEN (Intrexon)|Forward Price-to-Revenue Multiple PHAR (Pharming)|NKTR (Nektar) - Forward Price to Sales|Forward P/S Multiple UPB (upstreambio.com)|ZBIO (Zenas Biopharma Inc) - Future Price to Revenue|Gossamer Bio Inc - Forward P/S Multiple|Forward Price to Sales KALV (KalVista Pharmaceuticals, Inc.)|SEPN: Forward P/S Multiple|Forward Price-to-Revenue Multiple Pieris Pharmaceuticals Inc|Forward Price-to-Revenue Multiple SVRA|Forward Price-to-Revenue Multiple Rigel Pharmaceuticals (RIGL)|Forward P/S Multiple ANAB|ATXS - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio enGene Corp ENGN|Market Cap to Expected Sales Ratio RAPT Therapeutics, Inc. (RAPT)|Aerovate - Forward P/S Multiple|ACRS - Forward P/S Multiple|KYTX (Kyverna Therapeutics) - Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Tiziana Life Sciences Ltd. (TLSA)|Forward Price-to-Revenue Multiple CABA|Ventyx Biosciences (VTYX) - Market Cap to Expected Sales Ratio|Forward P/S Multiple THTX|AVTX (Avalo Therapeutics, Inc) - Forward Price to Sales|Forward P/S Multiple ELDN (eledon.com)|AGEN - Forward Price-to-Revenue Multiple|CLYM - Price-to-Projected Revenue Ratio|Future Price to Revenue ZURA|ATYR: Forward P/S Multiple|Adagene Corp (ADAG) - Forward P/S Multiple|Forward Price-to-Revenue Multiple IMA|Shattuck Labs, Inc. - Future Price to Revenue|Price-to-Projected Revenue Ratio Equillium Inc (EQ)|Forward P/S Multiple Connect Biopharma Holdings (CNTB)|Price-to-Projected Revenue Ratio Immunic, Inc. IMUX|Forward P/S Multiple Atara Biotherapeutics ATRA|IFRX - Price-to-Projected Revenue Ratio|XFOR: Price-to-Projected Revenue Ratio|ACET: Forward P/S Multiple|CELU - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio inmunebio.com|Market Cap to Projected Revenue BRNS (barinthusbio.com)|Forward P/S Multiple KZR|Forward P/S Multiple SAB Biotherapeutics, Inc (SABS)|Forward P/S Multiple AKTX (Akari Therapeutics, Plc)|Forward P/S Multiple enlivex.com ENLV|QTTB: Forward Price-to-Revenue Multiple|GOVX - Forward P/S Multiple|Edesa Biotech Inc (EDSA) - Price-to-Projected Revenue Ratio|IBIO - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio carismatx.com|XTLB: Forward Price to Sales|Price-to-Projected Revenue Ratio Bolt Biotherapeutics Inc. (BOLT)|HCW Biologics - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio aptevotherapeutics.com APVO|AIM - Forward Price-to-Revenue Multiple|Aditxt - Forward P/S Multiple|Market Cap to Expected Sales Ratio GRI Bio Corporation GRI|xortx.com (XRTX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio reshapelifesciences.com (HIND)|Price-to-Projected Revenue Ratio Revelation Bio|Market Cap to Future Revenue Ratio Indaptus Therapeutics, Inc. INDP|Price-to-Projected Revenue Ratio BiondVax Pharmaceuticals (SCNI)|Forward Price-to-Revenue Multiple CalciMedica CALI|Price-to-Projected Revenue Ratio Affimed AFMD|ALLK - Forward Price-to-Revenue Multiple|HOOKIPA Pharma, Inc. - Forward P/S Multiple|Forward Price to Sales IGMS (igmbio.com)|ITOS (iTeos Therapeutics, Inc.) - Forward Price-to-Revenue Multiple|Ocean Biomedical Corp (OCEA) - Forward P/S Multiple|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|Forward P/S Multiple thirdharmonicbio.com
